

MJ BIOSCIENCE CORP.

Suite 1080, 789 West Pender Street
Vancouver, BC V6C 1H2

MJ BIOSCIENCE ADVISES OF AMENDED MD&A AND MANAGEMENT CERTIFICATIONS

June 14, 2018

Vancouver, B.C., June 14, 2018 – As a result of a review by the British Columbia Securities Commission, **MJ Bioscience Corp.** (“**MJ Bioscience**” or the “**Company**”) is issuing the following news release to clarify its disclosure contained in its Management’s Discussion and Analysis for the three months ended January 31, 2018, (the “**MD&A**”) as filed under the Company’s profile on the **System** for **Electronic** Document Analysis and Retrieval (“**SEDAR**”) at www.sedar.com on April 9, 2018.

MJ Bioscience has filed an amended and restated MD&A to provide more detail with respect to the Company’s current and future business activities; include a discussion of factors that have caused variations over the eight quarters necessary to understand general trends that have developed, with a particular focus on disclosure of causes in the significant change in net income/loss for the quarters ended January 31, 2018, and October 31, 2017; provide an analysis of the Company’s liquidity; and identify certain related persons or entities, with enhanced disclosure pertaining to the business purpose of the related party transaction and the recorded amount of the transaction.

In connection with the filing of the amended and restated MD&A, the Company has filed the requisite management certifications. These forms and the amended and restated MD&A are available for viewing on SEDAR.

On behalf of the Board of Directors,
MJ BIOSCIENCE CORP.

“Brent Hahn”
Director, Chief Executive Officer, and Director

For more information, please contact the Company at:
Telephone: 604-428-7050